Is NTLA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Positive Late-Stage Lonvo-z Data in Hereditary Angioedema, with revenue at Collaboration revenue only (e.g., Regeneron); no product revenue yet. The bear case rests on intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. Analysts covering it are spread from $8.00 to $95.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $8.00, -24.5% from the $10.60 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Positive Late-Stage Lonvo-z Data in Hereditary Angioedema. In 2026 Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, including an approximately 87 percent reduction in mean monthly attacks versus placebo, with a majority of treated patients reported as attack-free over the efficacy period. The most optimistic analyst target on NTLA is $95.00, +796.2% from the $10.60 price. That figure is only reachable if this thesis works close to its best case.

Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The company burns roughly $90 million to $100 million per quarter and has repeatedly raised equity to extend its runway, so existing shareholders face ongoing dilution risk before any product profit materializes. Even with positive data, regulatory approval, reimbursement, and commercial adoption of a novel one-time gene-editing therapy are uncertain and could take years. The company also competes with better-capitalized CRISPR and gene-editing peers, with RNA-interference and stabilizer drugs already approved in ATTR, and with established prophylaxis options in hereditary angioedema. The most pessimistic published target is $8.00, -24.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Intellia Therapeutics, Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Positive Late-Stage Lonvo-z Data in Hereditary Angioedema) stalling in the reported numbers rather than in the narrative, the risk above (intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Intellia Therapeutics is a clinical-stage biotechnology company that develops genome-editing medicines using CRISPR/Cas9. Its specialty is in vivo editing, delivering the editing machinery directly into the body so a single dose can permanently alter a disease-causing gene. Its two lead programs are lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis, the latter partnered with Regeneron Pharmaceuticals.

That depends entirely on an investor's risk tolerance and time horizon, and this is not advice. The bull case is positive Phase 3 lonvo-z data, an active FDA filing, a Regeneron-partnered ATTR program, and a validated in vivo platform. The bear case is that NTLA is pre-revenue, unprofitable, burns roughly $90 to $100 million per quarter, and depends on binary trial and regulatory outcomes that can move the stock sharply.

No. Intellia is a clinical-stage, pre-revenue company that records only collaboration revenue and has no approved products generating sales. It reported a net loss of roughly $96 million in the first quarter of 2026 and funds operations through cash reserves and periodic equity raises. Profitability would depend on successfully bringing lonvo-z, nex-z, or another program to market, which has not yet happened.